ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1047

Clinical Characteristics and Treatment Pattern in Patients with CKD: Real-World Insights from iCaReMe Registry-Middle East and Africa (MEA) Cohort

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Arici, Mustafa, Hacettepe University Medical Faculty, Ankara, Turkey
  • Aoun Bahous, Sola, Lebanese American University School of Medicine, Beirut, Lebanon
  • Naidu, Kuven, Life Glynnwood Hospital, Benoni, South Africa
  • Barghouthi, Hiba M., Abdali Medical Center, Amman, Jordan
  • Nooryani, Arif Al, Al Qassimi Hospital, Sharjah, Sharjah, United Arab Emirates
  • Kamano, Jemima Hoine, Moi Teaching and Referral Hospital, Eldoret, Uasin Gishu, Kenya
  • Reja, Ahmed, Addis Ababa University College of Health Sciences, Addis Ababa, Addis Ababa, Ethiopia
  • Salah Eldin, Mohamed, National Institute of Urology and Nephrology, Cairo, Egypt
  • Eren, Necmi, Kocaeli University, Kocaeli, Turkey
  • Goncalves, Susana, AstraZeneca Argentina, Buenos Aires, Argentina
  • Nguyen Cong, Luong, AstraZeneca Vietnam, Ho Chi Minh City, Viet Nam
  • Hadaoui, Ahmed, AstraZeneca Algeria, Algiers, Algeria

The global burden of CKD has witnessed a nearly 30% rise in past 30 years with increasing prevalence of hypertension (HTN) and type 2 diabetes (T2D). The MEA region shares disproportionate burden of CKD with paucity of data on patients’ characteristics and management. The iCaReMe Global Registry (NCT03549754 multinational, prospective, observational study) aims to generate real world data on characteristics, management patterns, and outcomes in patients with CKD, T2D, HTN, or HF.


Baseline cross sectional descriptive analysis of clinicodemographic characteristics and treatment patterns in CKD patients enrolled from MEA region in the iCaReMe registry between February 2018 and December 2022.


1629 adults with CKD (mean±SD age; 59.7±14.5years, 56.1% male) were enrolled from 8 MEA countries (Egypt, Ethiopia, Jordan, Kenya, Lebanon, South Africa, Turkey, and United Arab Emirates). HTN (75.6%), T2D (54.4%) and HF (36.4%) were the most common comorbidities. UACR and eGFR were available in 31.7% and 79.1% of patients, respectively while 10.9% had both. The prevalence of KDIGO GFR G3-5 was 77.0% and albuminuria A2/A3 was 72.5%. The medications included ARB (26.5%) and ACEi (11.0%); about 19.6% were on SGLT2i. (Figure)


Most of the enrolled patients were at high/very high risk of CKD progression. Only one third had UACR testing. Less than one third received optimal guideline-directed medical therapy (GDMT). Our results highlight underutilization of UACR screening and suboptimal adherence to GDMT in patients with CKD in the MEA region.


  • Commercial Support – AstraZeneca